Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Regeneron Pharmaceuticals (REGN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.1%. By the end of trading, Regeneron Pharmaceuticals fell $1.63 (-1.2%) to $136.43 on light volume. Throughout the day, 347,622 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 946,300 shares. The stock ranged in price between $135.73-$138.37 after having opened the day at $138.06 as compared to the previous trading day's close of $138.06. Other companies within the Health Care sector that declined today were: Palatin Technologies (PTN), down 12.6%, Retractable Technologies (RVP), down 10.3%, BG Medicine (BGMD), down 10%, and Aastrom Biosciences (ASTM), down 8.8%.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $13.12 billion and is part of the drugs industry. Shares are up 149.1% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, compelling growth in net income, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

• You can view the full Regeneron Ratings Report.

On the positive front, Rosetta Genomics (ROSG), up 23.4%, Coventry Health Care (CVH), up 20.3%, Cormedix (CRMD), up 19.8%, and Repros Therapeutics (RPRX), up 15.2%, were all gainers within the health care sector with Varian Medical Systems (VAR) being today's featured health care sector leader.

• Use our health care section to find sector-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

• Find other investment ideas from our top rated ETFs lists.

For more information on Regeneron Pharmaceuticals Inc. click any of the following:

• Regeneron Pharmaceuticals Inc. Stock Price

• Regeneron Pharmaceuticals Inc. Analyst Ratings

• Regeneron Pharmaceuticals Inc. Key Stats & Profile

• Regeneron Pharmaceuticals Inc. Earnings

• Regeneron Pharmaceuticals Inc. Ratio Comparison

• Regeneron Pharmaceuticals Inc. Growth Rates

• Regeneron Pharmaceuticals Inc. Balance Sheet

• Regeneron Pharmaceuticals Inc. Cash Flow

• Regeneron Pharmaceuticals Inc. Income Statement